Common Contracts
11 similar Sales Agreement contracts by Aduro Biotech, Inc., Amicus Therapeutics Inc, AVROBIO, Inc., others
SOPHiA GENETICS SA SALES AGREEMENTSales Agreement • August 8th, 2023 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
SOPHiA GENETICS SA, a corporation (société anonyme) incorporated under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
COMMON STOCK SALES AGREEMENTSales Agreement • November 8th, 2022 • AVROBIO, Inc. • Biological products, (no disgnostic substances) • New York
ORPHAZYME A/S AMERICAN DEPOSITARY SHARES EACH REPRESENTING ONE ORDINARY SHARE SALES AGREEMENTSales Agreement • November 4th, 2021 • Orphazyme a/S • Pharmaceutical preparations • New York
Orphazyme A/S, a public limited liability company (Aktieselskab) organized and existing under the laws of the Kingdom of Denmark (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
TRICIDA, INC. COMMON STOCK SALES AGREEMENTSales Agreement • January 22nd, 2021 • Tricida, Inc. • Pharmaceutical preparations • New York
Tricida, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
OYSTER POINT PHARMA, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 5th, 2020 • Oyster Point Pharma, Inc. • Biological products, (no disgnostic substances) • New York
Oyster Point Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ADURO BIOTECH, INC. cOMMON STOCK SALES AGREEMENTSales Agreement • August 2nd, 2017 • Aduro Biotech, Inc. • Pharmaceutical preparations • New York
TURNING POINT BRANDS, INC. $50,000,000 COMMON STOCK FORM OF SALES AGREEMENTSales Agreement • June 30th, 2017 • Turning Point Brands, Inc. • Tobacco products • New York
Turning Point Brands, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
OXFORD IMMUNOTEC GLOBAL PLC $40,000,000 ORDINARY SHARES SALES AGREEMENTSales Agreement • December 21st, 2016 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
Oxford Immunotec Global PLC (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
AMICUS THERAPEUTICS, INC. $100,000,000 OF SHARES COMMON STOCK (PAR VALUE $0.01 PER SHARE) SALES AGREEMENTSales Agreement • February 26th, 2016 • Amicus Therapeutics Inc • Pharmaceutical preparations • New York
Amicus Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
COMMON STOCK SALES AGREEMENTSales Agreement • December 23rd, 2013 • Endocyte Inc • Pharmaceutical preparations • New York
RAPTOR PHARMACEUTICAL CORP. SALES AGREEMENTSales Agreement • May 1st, 2012 • Raptor Pharmaceutical Corp • Pharmaceutical preparations • New York
Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
